By Randy Osborne
Last week's phase III blowup of Eli Lilly and Co.'s solanezumab(sola) in Alzheimer's disease (AD) struck up a familiar dirge in the failure-strewn space, and set experts to debating β again, still β the amyloid beta hypothesis, as companies that have chosen to pursue other routes continued to laud their approaches and ever-ambitious big pharma snatched up another player in the space.
Read full article here: http://www.bioworld.com/content/so-long-sola-lilly-bloom%E2%80%99s-hope-withers-big-pharma-continues-%E2%80%98chase%E2%80%99-ad-dream-0